MC

448.85

+2.56%↑

SANES

7

+1.91%↑

ALV

343

+0.91%↑

BNP

76.72

+1.68%↑

BBVA

12.965

+1.65%↑

MC

448.85

+2.56%↑

SANES

7

+1.91%↑

ALV

343

+0.91%↑

BNP

76.72

+1.68%↑

BBVA

12.965

+1.65%↑

MC

448.85

+2.56%↑

SANES

7

+1.91%↑

ALV

343

+0.91%↑

BNP

76.72

+1.68%↑

BBVA

12.965

+1.65%↑

MC

448.85

+2.56%↑

SANES

7

+1.91%↑

ALV

343

+0.91%↑

BNP

76.72

+1.68%↑

BBVA

12.965

+1.65%↑

MC

448.85

+2.56%↑

SANES

7

+1.91%↑

ALV

343

+0.91%↑

BNP

76.72

+1.68%↑

BBVA

12.965

+1.65%↑

Evotec AG

Затворен

СекторФинансови

7.14 -0.42

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

7.05

Максимум

7.25

Ключови измерители

By Trading Economics

Приходи

9.3M

-32M

Продажби

-21M

200M

EPS

-0.23

Марж на печалбата

-15.79

Служители

4,766

EBITDA

-16M

-27M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+39.86% upside

Дивиденти

By Dow Jones

Следващи печалби

13.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-197M

1.2B

Предишно отваряне

7.56

Предишно затваряне

7.14

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Evotec AG Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.06.2025 г., 13:21 ч. UTC

Пазарно говорене

Volkswagen, BASF, DHL Owner Could Issue Profit Warnings -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Evotec AG Прогноза

Ценова цел

By TipRanks

39.86% нагоре

12-месечна прогноза

Среден 10.07 EUR  39.86%

Висок 11.9 EUR

Нисък 7 EUR

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Evotec AG през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

2

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

6.766 / 7.746Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Weak Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Evotec AG

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.